tbuckley/cabot-search huggingface dataset:
WHO global research priorities for antimicrobial resistance in human health
Authors: Silvia Bertagnolio, Zlatina Dobreva, Chad M Centner, Ioana Diana Olaru, Daniele Donà, Stefano Burzo, Benedikt D Huttner, Antoine Chaillon, Nebiat Gebreselassie, Teodora Wi, Mateusz Hasso-Agopsowicz, Benedetta Allegranzi, Hatim Sati, Verica Ivanovska, Kavita U Kothari, Hanan H Balkhy, Alessandro Cassini, Raph L Hamers, Kitty Van Weezenbeek
Journal: The Lancet Microbe (2024)

The WHO research agenda for antimicrobial resistance (AMR) in human health has identified 40 research priorities to be addressed by the year 2030. These priorities focus on bacterial and fungal pathogens of crucial importance in addressing AMR, including drug-resistant pathogens causing tuberculosis. These research priorities encompass the entire people-centred journey, covering prevention, diagnosis, and treatment of antimicrobial-resistant infections, in addition to addressing the overarching knowledge gaps in AMR epidemiology, burden and drivers, policies and regulations, and awareness and education. The research priorities were identified through a multistage process, starting with a comprehensive scoping review of knowledge gaps, with expert inputs gathered through a survey and open call. The priority setting involved a rigorous modified Child Health and Nutrition Research Initiative approach, ensuring global representation and applicability of the findings. The ultimate goal of this research agenda is to encourage research and investment in the generation of evidence to better understand AMR dynamics and facilitate policy translation for reducing the burden and consequences of AMR.
Distinctive evolution of alveolar T cell responses is associated with clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia
Authors: Nikolay S. Markov, Ziyou Ren, Karolina J. Senkow, Rogan A. Grant, Catherine A. Gao, Elizabeth S. Malsin, Lango Sichizya, Hermon Kihshen, Kathryn A. Helmin, Milica Jovisic, Jason M. Arnold, Xóchitl G. Pérez-Leonor, Hiam Abdala-Valencia, Suchitra Swaminathan, Julu Nwaezeapu, Mengjia Kang, Luke Rasmussen, Egon A. Ozer, Ramon Lorenzo-Redondo, Judd F. Hultquist, Lacy M. Simons, Estefany Rios-Guzman, Alexander V. Misharin, Richard G. Wunderink, G. R. Scott Budinger, Benjamin D. Singer, Luisa Morales-Nebreda, Hiam Abdala-Valencia, Luke V. Rasmussen, Judd Hultquist, Lacy Simmons, Estefany R. Guzman, Michael J. Alexander, Arghavan Alisoltanidehkordi, Joseph I. Bailey, Elizabeth T. Bartom, Ankit Bharat, Thomas Bolig, Nicole Borkowski, Navdeep S. Chandel, Rebecca K. Clepp, John Coleman, Michael J. Cuttica, Thaddeus R. Cybulski, Jane E. Dematte, Joseph S. Deters, Estefani Diaz, Alvaro Donayre, Helen K. Donnelly, Justin A. Fiala, Gaurav T. Gadhvi, Khalilah L. Gates, Samuel W. M. Gatesy, Pearl D. Go, Cara J. Gottardi, Stefan J. Green, Elen Gusman, SeungHye Han, Erica Marie Hartmann, Alan R. Hauser, Curt M. Horvath, Mishaal Hukamdad, Sydney M. Hyder, Manu Jain, Emmy Jonasson, Anthony M. Joudi, Rachel B. Kadar, Ravi Kalhan, David W. Kamp, Manoj Kandpal, David A. Kidd, Zasu M. Klug, Erin A. Korth, Jacqueline M. Kruser, Romy Lawrence, Emily M. Leibenguth, Anne R. Levenson, Lindsey D. Gradone, Gabrielle Y. Liu, Jon W. Lomasney, Theresa A. Lombardo, Ziyan Lu, Amy Ludwig, Ali Mahmoud, Alexandra C. McQuattie-Pimentel, Daniel Meza, Ruben J. Mylvaganam, Prasanth Nannapaneni, Sophia Nozick, Luís A. Nunes Amaral, Radhika Patel, Anna E. Pawlowski, Chiagozie O. Pickens, Yuliya Politanska, Taylor A. Poor, Michelle H. Prickett, Chao Qi, Melissa Querrey, Karen M. Ridge, Madeline L. Rosenbaum, Sharon R. Rosenberg, Timothy Rowe, Susan R. Russell, Marc A. Sala, Daniel Schneider, Clara J. Schroedl, Katharine Secunda, Patrick C. Seed, Elisheva D. Shanes, Jiaxian Shen, Ali Shilatifard, Sean Smith, Peter H. S. Sporn, Justin Starren, Thomas Stoeger, Jack Sumner, Jacob I. Sznajder, Lindsey N. Textor, Sanket Thakkar, Rade Tomic, Betty Tran, Kaitlyn Vitale, Ajay A. Wagh, James M. Walter, Firas Wehbe, Deborah R. Winter, Alexis R. Wolfe, Lisa F. Wolfe, Anjana V. Yeldandi, Zhan Yu, Jose Castellanos, Lars Johnson, Scott Laurenzo, Gabrielle Matias, Emily M. Olson, Jamie Rowell, Ashley Smith-Nunez, Alison Szabo, Brian White
Journal: Nature Immunology (2024)
Comment on “Evidence Synthesis of Observational Studies in Environmental Health: Lessons Learned from a Systematic Review on Traffic-Related Air Pollution”
Authors: Kyla W. Taylor, Kembra L. Howdeshell, Anisha Singh, Vickie R. Walker, Amy Wang, Abee E. Boyles, Brandiese E.J. Beverly, Andrew A. Rooney
Journal: Environmental Health Perspectives (2024)
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Authors: Jeremy W. Jacobs, Caroline G. Stanek, Garrett S. Booth, Argiris Symeonidis, Andrew W. Shih, Elizabeth S. Allen, Eleni Gavriilaki, Brenda J. Grossman, Katerina Pavenski, Amy Moorehead, Flora Peyvandi, Pasquale Agosti, Ilaria Mancini, Laura D. Stephens, Jay S. Raval, Maria Eva Mingot‐Castellano, Elizabeth P. Crowe, Laetitia Daou, Menaka Pai, Donald M. Arnold, Marisa B. Marques, Ryan Henrie, Tyler W. Smith, Gayatri Sreenivasan, Rance C. Siniard, Lisa R. Wallace, Chisa Yamada, Miriam Andrea Duque, Yanyun Wu, Thomas J. Harrington, Diana M. Byrnes, Aikaterini Bitsani, Amanda K. Davis, Danielle H. Robinson, Quentin Eichbaum, Cristina A. Figueroa Villalba, Justin E. Juskewitch, Georgia Kaiafa, Eleni Kapsali, Ellen Klapper, Ingrid Perez‐Alvarez, Monica S. Klein, Nikolaos Kotsiou, Chrysavgi Lalayanni, Evdokia Mandala, Fatima Aldarweesh, Rahaf Alkhateb, Lisandro Fortuny, Zois Mellios, Apostolia Papalexandri, Meredith G. Parsons, Annette J. Schlueter, Christopher A. Tormey, Cameron Wellard, Erica M. Wood, Shiyang Jia, Allison P. Wheeler, Amy A. Powers, Christopher B. Webb, Sean G. Yates, Raïda Bouzid, Paul Coppo, Evan M. Bloch, Brian D. Adkins
Journal: American Journal of Hematology (2024)

Prior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5-year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere-winter (December-February); spring (March-May); summer (June-August); autumn (September-November) and Southern Hemisphere-winter (June-August); spring (September-November); summer (December-February); autumn (March-May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%-31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.
Integration of epidemiological and blood biomarker analysis links haem iron intake to increased type 2 diabetes risk
Authors: Fenglei Wang, Andrea J. Glenn, Anne-Julie Tessier, Zhendong Mei, Danielle E. Haslam, Marta Guasch-Ferré, Deirdre K. Tobias, A. Heather Eliassen, JoAnn E. Manson, Clary Clish, Kyu Ha Lee, Eric B. Rimm, Dong D. Wang, Qi Sun, Liming Liang, Walter C. Willett, Frank B. Hu
Journal: Nature Metabolism (2024)
Chloroplast and whole-genome sequencing shed light on the evolutionary history and phenotypic diversification of peanuts
Authors: Zheng Zheng, Ziqi Sun, Feiyan Qi, Yuanjin Fang, Ke Lin, Stefano Pavan, Bingyan Huang, Wenzhao Dong, Pei Du, Mengdi Tian, Lei Shi, Jing Xu, Suoyi Han, Hua Liu, Li Qin, Zhongxin Zhang, Xiaodong Dai, Lijuan Miao, Ruifang Zhao, Juan Wang, Yanlin Liao, Alun Li, Jue Ruan, Chiara Delvento, Riccardo Aiese Cigliano, Chris Maliepaard, Yuling Bai, Richard G. F. Visser, Xinyou Zhang
Journal: Nature Genetics (2024)

Abstract Cultivated peanut ( Arachis hypogaea L.) is a widely grown oilseed crop worldwide; however, the events leading to its origin and diversification are not fully understood. Here by combining chloroplast and whole-genome sequence data from a large germplasm collection, we show that the two subspecies of A. hypogaea ( hypogaea and fastigiata ) likely arose from distinct allopolyploidization and domestication events. Peanut genetic clusters were then differentiated in relation to dissemination routes and breeding efforts. A combination of linkage mapping and genome-wide association studies allowed us to characterize genes and genomic regions related to main peanut morpho-agronomic traits, namely flowering pattern, inner tegument color, growth habit, pod/seed weight and oil content. Together, our findings shed light on the evolutionary history and phenotypic diversification of peanuts and might be of broad interest to plant breeders.
<i>Vital Signs:</i> Trends and Disparities in Childhood Vaccination Coverage by Vaccines for Children Program Eligibility — National Immunization Survey-Child, United States, 2012–2022
Authors: Madeleine R. Valier, David Yankey, Laurie D. Elam-Evans, Michael Chen, Holly A. Hill, Yi Mu, Cassandra Pingali, Juan A. Gomez, Bayo C. Arthur, Tamara Surtees, Samuel B. Graitcer, Nicole F. Dowling, Shannon Stokley, Georgina Peacock, James A. Singleton
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

The Vaccines for Children (VFC) program was established in 1994 to provide recommended vaccines at no cost to eligible children and help ensure that all U.S. children are protected from life-threatening vaccine-preventable diseases.
Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies
Authors: Bojana Jovanović, Sarah E. Church, Kara M. Gorman, Khrystyna North, Edward T. Richardson, Molly DiLullo, Victoria Attaya, Julie Kasparian, Ayesha Mohammed-Abreu, Gregory Kirkner, Melissa E. Hughes, Nancy U. Lin, Elizabeth A. Mittendorf, Stuart J. Schnitt, Sara M. Tolaney, Shom Goel
Journal: Clinical Cancer Research (2024)

Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in development are frequently targeted toward tumors carrying a specific genomic, transcriptomic, or protein biomarker, it is poorly understood how these biomarkers are correlated.
Novel humanized monoclonal antibodies against ROR1 for cancer therapy
Authors: Rong Wei, Xun Liao, Jiao Li, Xiaoyu Mu, Yue Ming, Yong Peng
Journal: Molecular Cancer (2024)

Overexpression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) contributes to cancer cell proliferation, survival and migration, playing crucial roles in tumor development. ROR1 has been proposed as a potential therapeutic target for cancer treatment. This study aimed to develop novel humanized ROR1 monoclonal antibodies and investigate their anti-tumor effects. ROR1 expression in tumor tissues and cell lines was analyzed by immunohistochemistry and flow cytometry. Antibodies from mouse hybridomas were humanized by the complementarity-determining region (CDR) grafting technique. Surface plasmon resonance spectroscopy, ELISA assay and flow cytometry were employed to characterize humanized antibodies. In vitro cellular assay and in vivo mouse experiment were conducted to comprehensively evaluate anti-tumor activity of these antibodies. ROR1 exhibited dramatically higher expression in lung adenocarcinoma, liver cancer and breast cancer, and targeting ROR1 by short-hairpin RNAs significantly inhibited proliferation and migration of cancer cells. Two humanized ROR1 monoclonal antibodies were successfully developed, named h1B8 and h6D4, with high specificity and affinity to ROR1 protein. Moreover, these two antibodies effectively suppressed tumor growth in the lung cancer xenograft mouse model, c-Myc/Alb-cre liver cancer transgenic mouse model and MMTV-PyMT breast cancer mouse model. Two humanized monoclonal antibodies targeting ROR1, h1B8 and h6D4, were successfully developed and exhibited remarkable anti-tumor activity in vivo.
Augmentation of Tendon and Ligament Repair with Fiber‐Reinforced Hydrogel Composites
Authors: Robert N. Kent, Alice H. Huang, Brendon M. Baker
Journal: Advanced Healthcare Materials (2024)

This review highlights the promise of fiber-reinforced hydrogel composites (FRHCs) for augmenting tendon and ligament repair and regeneration. Composed of reinforcing fibers embedded in a hydrogel, these scaffolds provide both mechanical strength and a conducive microenvironment for biological processes required for connective tissue regeneration. Typical properties of FRHCs are discussed, highlighting their ability to simultaneously fulfill essential mechanical and biological design criteria for a regenerative scaffold. Furthermore, features of FRHCs are described that improve specific biological aspects of tendon healing including mesenchymal progenitor cell recruitment, early polarization to a pro-regenerative immune response, tenogenic differentiation of recruited progenitor cells, and subsequent production of a mature, aligned collagenous matrix. Finally, the review offers a perspective on clinical translation of tendon FRHCs and outlines key directions for future work.
Endodontic surgery and platelet concentrates: A comprehensive review
Authors: Mohammad Sabeti, Julian Gabbay, Armin AI
Journal: Periodontology 2000 (2024)

While autologous platelet concentrates (APCs) have gained traction as promising regenerative materials in recent years, their impact on wound healing and tissue regeneration in periapical hard tissue defects remains controversial. Endodontic microsurgery (EMS) has embraced the potential of platelet concentrates, particularly L-PRF (Leucocyte-Platelet-Rich Fibrin) and PRP (Platelet-Rich Plasma), as regenerative tools. These concentrates, rich in growth factors and other bioactive molecules, are thought to enhance healing and treatment outcomes for various endodontic conditions. However, their effectiveness remains a subject of investigation. Despite encouraging 3-D cone beam computed tomography (CBCT) based evidence for PRP's effectiveness in complex lesions and apico-marginal defects, inconsistencies in its performance across preparation and application protocols raise questions about its superiority over existing options. More research is crucial to understand its full potential as a reliable regenerative tool in endodontics. L-PRF and its derivatives are particularly effective in treating apical-marginal defects. It enhances clinical attachment levels and reduces probing pocket depths, likely due to its slow and coordinated release of various growth factors. L-PRF has been shown to also improve patients' quality of life by reducing postoperative swelling and pain. However, more research is needed to standardize its preparation methods and confirm its long-term benefits. This paper aims to provide a comprehensive review of the current knowledge and recent advances in endodontic surgery and the use of platelet concentrates, focusing on their roles in managing periapical lesions and endo-perio lesions.
Tumor Microenvironment Reprogrammed Bimetallic Hybrid Nanostimulator for Triggering Radio‐Cuproptosis‐Immunotherapy
Authors: Xiaohong Jiang, Jin Wang, Weijie Huang, Haowei Ma, Shilong Zhang, Zehong Cai, Wenxin Lin, Jintao Zheng
Journal: Advanced Healthcare Materials (2024)

Radio-immunotherapy driven by radiation-induced immunogenic cell death (ICD) is emerging as a potential opportunity to address conventional radiotherapy (RT) that is only applicable to localized tumor treatment. However, the effective activation of ICD during RT is severely limited by radiation dose, weak tumor immunogenicity, and radio-resistance caused by tumor microenvironment (TME). Herein, a novel bimetallic hybrid nanoscale coordination nanostimulator is first proposed by phosphate backbone doped with copper ions (Cu
Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis
Authors: Han Ah Lee, Mi Na Kim, Hye Ah Lee, Miyoung Choi, Jung Hwan Yu, Young-Joo Jin, Hee Yeon Kim, Ji Won Han, Seung Up Kim, Jihyun An, Young Eun Chon
Journal: Clinical and Molecular Hepatology (2024)

Backgrounds/Aims: Despite advances in antiviral therapy for hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC) still develops even after sustained viral response (SVR) in patients with advanced liver fibrosis or cirrhosis. This meta-analysis investigated the predictive performance of vibration-controlled transient elastography (VCTE) and fibrosis 4-index (FIB-4) for the development of HCC after SVR.Methods: We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for studies examining the predictive performance of these tests in adult patients with HCV. Two authors independently screened the studies’ methodological quality and extracted data. Pooled estimates of sensitivity, specificity, and area under the curve (AUC) were calculated for HCC development using random-effects bivariate logit normal and linear-mixed effect models.Results: We included 27 studies (169,911 patients). Meta-analysis of HCC after SVR was possible in nine VCTE and 15 FIB-4 studies. Regarding the prediction of HCC development after SVR, the pooled AUCs of pre-treatment VCTE &gt;9.2–13 kPa and FIB-4 &gt;3.25 were 0.79 and 0.73, respectively. VCTE &gt;8.4–11 kPa and FIB-4 &gt;3.25 measured after SVR maintained good predictive performance, albeit slightly reduced (pooled AUCs: 0.77 and 0.70, respectively). The identified optimal cut-off value for HCC development after SVR was 12.6 kPa for pre-treatment VCTE. That of VCTE measured after the SVR was 11.2 kPa.Conclusions: VCTE and FIB-4 showed acceptable predictive performance for HCC development in patients with HCV who achieved SVR, underscoring their utility in clinical practice for guiding surveillance strategies. Future studies are needed to validate these findings prospectively and validate their clinical impact.
The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research
Authors: Aurélie Moniot, Christophe Schneider, Laure Chardin, Elisa Yaniz-Galende, Catherine Genestie, Marion Etiennot, Aubéri Henry, Coralie Drelon, Audrey Le Formal, Benoit Langlois, Laurence Venat, Christophe Louvet, Laure Favier, Alain Lortholary, Dominique Berton-Rigaud, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Coraline Dubot, Jean Emmanuel Kurtz, Nathalie Bonichon Lamichhane, Éric Pujade-Lauraine, Albin Jeanne, Alexandra Leary, Stéphane Dedieu
Journal: Molecular Cancer (2024)

Abstract Background Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC, many patients will relapse and the PARPi-resistant setting is an area of unmet medical need. Traditional immunotherapies targeting PD-1/PD-L1 have failed to show any benefit in OC. The CD47/TSP-1 axis may be relevant in OC. We aimed to describe changes in CD47 expression with platinum therapy and their relationship with immune features and prognosis. Methods Tumor and blood samples collected from OC patients in the CHIVA trial were assessed for CD47 and TSP-1 before and after neoadjuvant chemotherapy (NACT) and multiplex analysis was used to investigate immune markers. Considering the therapeutic relevance of targeting the CD47/TSP-1 axis, we used the CD47-derived TAX2 peptide to selectively antagonize it in a preclinical model of aggressive ovarian carcinoma. Results Significant reductions in CD47 expression were observed post NACT. Tumor patients having the highest CD47 expression profile at baseline showed the greatest CD4 + and CD8 + T-cell influx post NACT and displayed a better prognosis. In addition, TSP-1 plasma levels decreased significantly under NACT, and high TSP-1 was associated with a worse prognosis. We demonstrated that TAX2 exhibited a selective and favorable biodistribution profile in mice, localizing at the tumor sites. Using a relevant peritoneal carcinomatosis model displaying PARPi resistance, we demonstrated that post-olaparib (post-PARPi) administration of TAX2 significantly reduced tumor burden and prolonged survival. Remarkably, TAX2 used sequentially was also able to increase animal survival even under treatment conditions allowing olaparib efficacy. Conclusions Our study thus (1) proposes a CD47-based stratification of patients who may be most likely to benefit from postoperative immunotherapy, and (2) suggests that TAX2 is a potential alternative therapy for patients relapsing on PARP inhibitors.
Leveraging insights from cancer to improve tuberculosis therapy
Authors: Meenal Datta, Laura E. Via, Véronique Dartois, Lei Xu, Clifton E. Barry, Rakesh K. Jain
Journal: Trends in Molecular Medicine (2024)

Exploring and exploiting the microenvironmental similarities between pulmonary tuberculosis (TB) granulomas and malignant tumors has revealed new strategies for more efficacious host-directed therapies (HDTs). This opinion article discusses a paradigm shift in TB therapeutic development, drawing on critical insights from oncology. We summarize recent efforts to characterize and overcome key shared features between tumors and granulomas, including excessive fibrosis, abnormal angiogenesis, hypoxia and necrosis, and immunosuppression. We provide specific examples of cancer therapy application to TB to overcome these microenvironmental abnormalities, including matrix-targeting therapies, antiangiogenic agents, and immune-stimulatory drugs. Finally, we propose a new framework for combining HDTs with anti-TB agents to maximize therapeutic delivery and efficacy while reducing treatment dosages, duration, and harmful side effects to benefit TB patients.